The cancer bloodhounds

@article{Webb2016TheCB,
  title={The cancer bloodhounds},
  author={Sarah M Webb},
  journal={Nature Biotechnology},
  year={2016},
  volume={34},
  pages={1090-1094}
}
Imagine a world in which a cancer diagnosis is possible from a simple blood draw. The allure of this idea is attracting a growing cadre of commercial acolytes. At the beginning of the year, Illumina announced that it was forming Grail, a cancer-screening company based in San Francisco, backed by >$100 million in private financing from such high-profile… CONTINUE READING